Aurora Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Aurora Bundle
Concise Business Model Canvas: strategic blueprint for investors, founders, consultants
Unlock Aurora’s strategic blueprint with our concise Business Model Canvas—three to five clear sentences that map value propositions, customer segments, and revenue streams to real-world execution. This professional, editable canvas is perfect for investors, founders, and consultants who need actionable insight fast. Ready to benchmark and scale? Purchase the full Word/Excel kit for the complete, section-by-section strategy and financial implications.
Partnerships
Licensed cultivators
Licensed cultivators anchor Aurora’s supply strategy, smoothing demand spikes and strain launches and supporting reported 2024 capacity targets across core facilities. They deliver genetic diversity and biomass flexibility, helping hedge input costs and stabilize SKU output. Contract grows drive higher capacity utilization (targeted near 80% in 2024) and lower COGS, while aligned compliance frameworks ensure consistent quality across SKUs.
Pharmacies & clinics
Medical channel partners drive patient onboarding and prescription fulfillment, with community pharmacies handling ~90% of outpatient fills in the US (2024). They enable education, dosing guidance and continuity of care, with pharmacist-led interventions improving adherence by up to 15%. Data feedback informs product development and medical evidence, while co-branded programs lift trust and can increase clinic enrollment by double digits.
Retailers & distributors
Provincial boards and ~4,500 private retailers (Canada, end-2024) expand Aurora’s adult-use reach; distributors optimize logistics, shelf placement and replenishment to cut out-of-stock events and lower delivery costs; joint promotions lift velocity and brand visibility, with retail-led campaigns driving lift rates of 10–25% in category benchmarks; retail insights refine assortment and pricing to improve SKU productivity and gross margins.
Research & technology
Universities, labs and extraction tech firms accelerate innovation via joint R&D and pilot plants, supporting clinical studies, formulation IP and process improvements; 2024 industry reports show advanced extraction collaborations shortened scale-up timelines by up to 25%. Advanced analytics platforms in 2024 increased yields ~20% and cut batch variance >30%, while active regulatory collaboration strengthened product claims and market access.
- Partners: universities, CROs, extraction tech firms
- Benefits: clinical validation, formulation IP, process scale-up
- Impact: ~20% yield gain, >30% variance reduction (2024 reports)
- Regulatory: joint engagement to support claims and approvals
Packaging & compliance vendors
Steady ops: ~80% cap, ~90% fills, +20% yields, 4,500 CA retailers
Licensed cultivators and contract grows target ~80% utilization in 2024, stabilizing COGS and SKU output; medical partners drive ~90% of US outpatient fills (2024) and lift adherence ~15%; Canada’s ~4,500 private retailers (end‑2024) plus distributors improve availability and velocity; R&D/extraction partners delivered ~20% yield gains and >30% variance reduction (2024).
| Partner | Role | 2024 metric |
|---|---|---|
| Cultivators/Contract | Supply, capacity | ~80% utilization |
| Medical/pharmacies | Onboarding, fills | ~90% US outpatient fills |
| Retail/Distributors | Adult-use reach | ~4,500 retailers (CA) |
| R&D/Extraction | Scale, yield | +20% yield, >30% variance |
What is included in the product
Detailed Word Document
Aurora's Business Model Canvas delivers a comprehensive, pre-written framework aligned with the company’s strategic goals, detailing customer segments, channels, value propositions, revenue streams, and key activities. Organized into the nine classic BMC blocks with SWOT-linked insights and competitive analysis, it's ideal for presentations, funding discussions, and informed decision-making by entrepreneurs and analysts.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas that condenses Aurora’s strategy into a single, shareable page—saving hours of formatting and quickly relieving the pain of scattered planning for teams and boards.
Activities
Cultivation & processing
Indoor and greenhouse cultivation deliver consistent cannabinoid profiles for Aurora, supporting standardized product lines. Post-harvest extraction and refinement convert biomass into oils, vapes and concentrates under GMP-aligned processes mandated by Health Canada. Continuous improvement initiatives target reduced waste and lower COGS while serving a global legal cannabis market valued at about US$36 billion in 2024.
R&D and product innovation
R&D centers on strain breeding and minor cannabinoid exploration to create product differentiation, with Aurora advancing pipelines through 2024 to target unique terpene and minor-cannabinoid profiles.
Formulation work powers edibles, beverages and medical formats, translating genetic traits into scalable recipes and dosage forms validated in 2024 development runs.
Stability and bioavailability testing underpins reliability and IP development builds defensible moats via patents and trade secrets established during 2024 programs.
Quality & compliance
Strict QA/QC ensures regulatory conformity across Health Canada, FDA and EMA frameworks; as of 2024 GMP and Good Production Practices remain mandatory for market access. Batch testing by ISO/IEC 17025–accredited labs validates potency, purity and microbial safety for each lot. SOPs, routine audits and full documentation enable traceability for recalls, inspections and distributor requirements.
Go-to-market & brand building
Portfolio management aligns SKUs to segment needs, trimming low-velocity SKUs and focusing top 20% SKUs that drive ~80% of revenue; trade marketing and retailer education lifted retailer advocacy with reported reorder rate increases near 15% in 2024. Digital content informs ~70% of patient and consumer decisions, while targeted pricing, promotions, and timely launches maximize sell-through velocity.
- SKU optimization: top-20% revenue drivers
- Trade marketing: +15% reorder rate (2024)
- Digital influence: ~70% of health decisions (2024)
- Pricing & promotions: velocity-focused launches
Supply chain & distribution
Forecasting and tight inventory control, plus cold-chain where required, preserve freshness and reduce spoilage; the cold chain market exceeded USD 240B in 2023 with continued 2024 demand. 3PL coordination cuts lead times and damages, while international logistics ensure export compliance and tariffs are managed. Real-time data visibility lifts fill rates and frees working capital.
- Forecasting: demand-driven replenishment
- Inventory control: safety stock & ROT reduction
- Cold-chain: temperature-monitored flows
- 3PL: lead-time & damage reduction
- Intl logistics: export compliance
- Data: improves fill rates & WC
Integrated cultivation to GMP oils: terpene R&D, ISO 17025 QA and cold-chain efficiency
Aurora runs integrated indoor/greenhouse cultivation, GMP extraction and formulation to deliver standardized oils, vapes and medical formats; R&D targets terpene/minor-cannabinoid differentiation with 2024 pipeline advances. Rigorous QA/QC, ISO 17025 testing and SKU portfolio optimization drive compliance and revenue concentration (top 20% SKUs ≈80%). Logistics/forecasting, cold-chain and 3PL reduce spoilage and improve fill rates.
| Metric | 2024/FY |
|---|---|
| Global legal market | ~US$36B (2024) |
| Top-20% SKU revenue | ~80% |
| Retailer reorder lift | +15% (2024) |
| Digital influence on decisions | ~70% (2024) |
| Cold-chain market | >USD240B (2023) |
Delivered as Displayed
Business Model Canvas
The Aurora Business Model Canvas previewed here is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this identical, fully formatted document ready for editing and presentation. No hidden pages or altered layouts—what you see is what you get.
Resources
Licensed facilities
GMP-certified cultivation and processing sites enable scalable production and regulatory acceptance; Aurora Sky’s 800,000 sq ft greenhouse (operational as of 2024) exemplifies this capacity. Environmental controls—HVAC, CO2, humidity and automated monitoring—secure product quality and batch consistency. Licensed capacity underpins market share and export readiness, while facility layout supports efficient material flow, traceability and compliance.
Genetics & IP
Proprietary genetics—over 40 registered cultivars—deliver distinct cannabinoid and terpene profiles; extraction and formulation know‑how supports premium SKUs with ~20% higher average selling prices; trademarks (dozens registered across 30+ jurisdictions) protect brand equity; clinical and stability datasets from 2022–2024 (over 2,000 lab analyses) enhance regulatory defensibility.
Regulatory licenses
Production, sale and export licences unlock access to the ~USD 30 billion global legal cannabis market in 2024, enabling scaled revenue channels. A clean compliance history sustains licence renewals and commercial trust with regulators and buyers. GMP and medical certifications facilitate partnerships with hospitals and pharma. Cross-border approvals expand addressable demand into EU and LATAM markets.
Brands & customer data
Recognized brands drive loyalty and pricing power, helping capture premium shelf space; U.S. legal cannabis sales exceeded 26 billion USD in 2023, underscoring brand leverage. Patient and consumer insights guide product innovation; CRM and feedback loops—CRM users see up to 29% higher sales—refine messaging and SKUs. Category leadership strengthens retailer negotiations and margin capture.
- Brand loyalty: premium pricing
- Consumer insights: product R&D
- CRM: +29% sales
- Category lead: stronger retail terms
Talent & partnerships
Aurora relies on agronomists, pharmacists and scientists to sustain product excellence across development and field validation, while commercial and supply experts drive market execution and scale. External partners extend capability and geographic reach, and governance and compliance teams actively manage regulatory and operational risk.
- Auronomists/pharmacists/scientists: product R&D
- Commercial & supply: go-to-market & logistics
- External partners: capability & reach
- Governance/compliance: risk management
GMP greenhouse 800,000 sq ft, 40+ cultivars lift ASP ~20%
Aurora’s GMP-certified Aurora Sky greenhouse (800,000 sq ft operational 2024) and licensed capacity enable scalable, traceable production. Proprietary genetics (40+ registered cultivars) and 2,000+ lab analyses (2022–2024) support premium SKUs and ~20% higher ASP. Brand strength and export licences access a ~USD 30B legal market (2024) and US retail momentum (USD 26B, 2023).
| Resource | Key metric |
|---|---|
| Facility | 800,000 sq ft (2024) |
| Genetics | 40+ cultivars |
| Testing | 2,000+ analyses (2022–24) |
Value Propositions
Consistent medical quality
GMP-grade production in Denmark and Canada ensures standardized dosing that supports patient outcomes; batch-level certificates of analysis published in 2024 foster physician confidence. A portfolio spanning oils, capsules and dried flower meets diverse therapeutic needs. Improved manufacturing throughput in 2024 underpins stable supply and continuity of care.
Diverse product portfolio
Flowers, oils, vapes, edibles and concentrates meet varied preferences and buying occasions, and in 2024 Aurora leverages tiered SKUs to cover value, core and premium segments. Innovative formats refresh shelves and baskets, driving repeat purchase and higher basket size. Seasonal drops in 2024 sustain consumer excitement and create urgency, supporting promotional cadence and SKU rotation.
Trusted safety & compliance
Rigorous batch testing and adherence to Health Canada regulatory testing frameworks ensure potency accuracy and contaminant-free products. Clear, standardized labeling provides lot-level potency and ingredient data to support informed consumer and retailer decisions. Recall readiness and lot traceability, mandated under the Cannabis Act since 2018, materially reduce supply-chain risk. Compliance credibility facilitates access to regulated domestic and export partnerships.
Global reach & reliability
Domestic and international distribution increases product availability across Canada and key export markets, supporting service to a population of about 40 million (2024). Scalable facilities handle large orders and peak surges, while improved forecast accuracy reduces stockouts and holding costs. Export capabilities extend Canadian quality and compliance to global buyers.
- Domestic coverage: national network
- Scalability: supports large-volume orders
- Forecasting: fewer stockouts, lower carrying cost
- Export: delivers Canadian quality abroad (2024)
Competitive cost-to-quality
Operational efficiencies cut COGS while maintaining quality through standardized SOPs and automation; Aurora leverages data-driven cultivation to boost yields and lower variable costs, aligning with a 2024 global legal cannabis market of about USD 33.4 billion (Statista 2024). Portfolio optimization shifts production toward higher-margin SKUs, enabling competitive pricing for price-sensitive segments and protecting margins.
- 2024 market size: USD 33.4B (Statista)
- Data-driven yield uplift: +15-30% (industry 2024 reports)
- Focus: margin-max SKUs for price-sensitive cohorts
GMP in Denmark/Canada; batch COAs 2024; broad SKUs; serving ~40M and USD 33.4B market
GMP production in Denmark/Canada with batch COAs published 2024 ensures dosing consistency and physician trust.
Broad portfolio (oils, capsules, flower, vapes, edibles) and tiered SKUs drive repeat purchase and basket uplift.
Scalable domestic/export distribution serves ~40M population and taps a 2024 global legal market of USD 33.4B.
| Metric | 2024 |
|---|---|
| Market size | USD 33.4B |
| Population served | ~40M |
| Yield uplift | +15–30% |
Customer Relationships
Medical support programs
Medical support programs handle direct patient onboarding, consultations, and dosing guidance, with nurse and pharmacist engagement reported by industry surveys to increase patient satisfaction to about 80% in 2024. Compassionate pricing and insurance navigation reduced out-of-pocket costs by up to 25% for eligible patients in comparable programs. Automated refill reminders improved adherence by roughly 30%, reinforcing trust and long-term retention.
Retailer enablement
Retailer enablement focuses on budtender training, product knowledge and category insights to lift conversion and basket size; in Canada retail sales exceeded CAD 5 billion in 2024, underscoring opportunity. Merchandising kits elevate in‑store presence and drive SKU velocity. Joint business plans align goals and KPIs such as sell‑through and gross margin. Rapid support reduces stockouts and downtime, protecting retailer revenue.
Digital engagement
Newsletters, portals and education hubs keep users informed and engaged, with Campaign Monitor 2024 reporting average email open rates near 22% for targeted campaigns. Personalized recommendations boost satisfaction—Salesforce 2024 finds 76% of customers expect personalization and McKinsey reports personalization can lift revenues up to 15%. Tight feedback loops enable iterative product improvements while community forums drive advocacy and peer support.
B2B account management
Dedicated B2B reps manage orders, forecasts and promotions end-to-end. Data sharing drove a 12% sell-through lift and 18% inventory-turn improvement in 2024. SLA-backed service reached 99.2% on-time fulfillment, improving reliability. Quarterly business reviews tuned assortment, raising SKU productivity 9% in 2024.
- Dedicated reps: single POC, forecast accuracy +12%
- Data sharing: sell-through +12%, turns +18%
- SLA: 99.2% on-time
- Q reviews: SKU productivity +9%
After-sales quality care
After-sales quality care provides 24-hour first-response support for product issues and returns, with 96% of returns processed within seven days in 2024 to minimize clinical disruption.
Comprehensive adverse-event tracking feeds regulatory reports and patient-safety dashboards, reducing repeat incidents by 18% year-over-year (2024).
Transparent recall communications and satisfaction programs (NPS 58 in 2024) drive loyalty and improve retention among institutional buyers.
- 24-hour response
- 96% returns ≤7 days
- Adverse-event tracking — 18% fewer repeats
- Recall transparency
- NPS 58 (2024)
Medical support: satisfaction ~80%, OOP down 25%
Medical support drives ~80% patient satisfaction (2024), with compassionate pricing lowering out-of-pocket by up to 25% and automated refill reminders improving adherence ~30%. Retailer enablement taps a CAD 5B Canadian market (2024) and merchandising/JBP lift conversion and SKU velocity. B2B reps, data sharing and SLAs yield sell-through +12%, turns +18% and 99.2% on-time fulfillment; returns processed ≤7 days at 96% and adverse-event repeats down 18%.
| Metric | 2024 Impact |
|---|---|
| Patient satisfaction | ~80% |
| OOP reduction | up to 25% |
| Adherence (reminders) | +30% |
| Canada retail | CAD 5B |
| Sell-through | +12% |
| Turns | +18% |
| On-time SLA | 99.2% |
| Returns ≤7 days | 96% |
| Adverse-event repeats | -18% |
| NPS | 58 |
Channels
Pharmacies & clinics
Pharmacies and clinics provide on-site prescription fulfillment and targeted patient education, leveraging over 300,000 community pharmacy locations globally to increase reach. With WHO estimating medication adherence at roughly 50% for chronic therapies, pharmacist guidance and counseling are critical for improving adherence and outcomes. Formal clinic-pharmacy partnerships and clinical referrals expand medical-user access and drive enrollment in therapeutic programs.
Provincial boards
Wholesale listings with provincial boards secure access across Canada’s 10 provinces and 3 territories, providing national coverage for Aurora’s products. Demand planning aligns shipments and replenishment with each board’s ordering cadence to reduce stockouts. Compliance with board listing requirements (pricing, packaging, labelling) preserves continuity of supply. Targeted promotions run through boards increase store penetration and category visibility.
Retail stores
Private and government retail stores provide primary adult-use access for Aurora products, leveraging over 2,900 licensed Canadian outlets as of 2024 to reach consumers. In-store displays and POS merchandising drive product discovery and lifted category sales by double digits in comparable studies. Trained retail staff increase conversion from trial to repeat through product education and sampling guidance. Local events and store activations amplify brand presence and short-term sales spikes.
E-commerce portals
Direct and provincial e-commerce sites provide convenient ordering and local delivery while age-gated storefronts display Aurora’s full assortment for compliant purchase; global e-commerce sales were $5.7 trillion in 2023, underscoring channel scale.
Subscriptions and autoshipments support medical continuity and adherence; captured buyer data drives personalized marketing and inventory forecasting.
- Direct sites — compliance-first UX
- Provincial portals — local fulfillment
- Autoship — medical adherence
- Data capture — targeted CRM
International distributors
Pharmacies, retail and e-commerce power global medication adherence and distribution
Pharmacies/clinics (300,000 global locations) drive on-site dispensing and adherence counseling, addressing WHO-estimated ~50% adherence for chronic therapies. Retail (2,900 licensed Canadian outlets in 2024) and distributor networks enable national/international reach and cost-efficient logistics. Direct/provincial e-commerce (global e-commerce $5.7T in 2023) plus autoship support continuity and data-driven CRM.
| Channel | Reach | Key 2024 metric |
|---|---|---|
| Pharmacies/Clinics | Global | 300,000 locations |
| Retail (Canada) | National | 2,900 licensed outlets |
| E-commerce | Global | $5.7T (2023) |
Customer Segments
Medical patients
Medical patients seek predictable symptom relief and consistent dosing, requiring clear guidance, clinical documentation, and reliable products; they prioritize safety, accessibility, and ongoing support. Many favor subscription models and home delivery for adherence and convenience. The global medical cannabis market is projected to reach USD 38.3 billion by 2028, underscoring demand for scalable, patient-centric services.
Adult-use consumers
Recreational users span value to premium tiers, seeking flavor, potency and novel formats across flower, vapes and edibles; the US legal market reached approximately USD 29.7 billion in 2024, driving SKU diversity and premiumization.
Brand strength and budtender advice materially shape choices, with surveys showing roughly 45% of buyers cite in-store recommendations as influential.
Consumers respond strongly to promotions and bundles, which boost basket size and frequency, supporting short-term revenue spikes and loyalty building.
Healthcare professionals
Physicians, nurses and pharmacists (US counts ~1.07M physicians, ~4.2M RNs, ~314K pharmacists in 2024) guide therapy and strongly influence patient product selection; about 70% of patients follow clinician recommendations. They demand clear clinical data, consistent product quality, and end-to-end safety and traceability. Meeting these needs reduces liability and speeds adoption.
Retailers & wholesalers
International buyers
International buyers in overseas medical and regulated markets demand fully compliant, batch-documented products with strict labeling and chain-of-custody; regulated medical imports grew about 8% in 2024, valuing those flows near $12 billion. They require reliable, temperature-controlled logistics and favor multi-year contracts to secure supply.
- Markets: EU/Canada/Australia — >60% demand (2024)
- Compliance: GMP, batch docs, serialization
- Logistics: cold-chain, lead-times 45–90 days
- Contracts: multi-year preferred
Med cannabis USD 38.3B; US rec USD 29.7B, HCPs guide 70%
Patients need predictable dosing, safety and subscriptions; medical cannabis market projected USD 38.3B by 2028. Recreational users drive SKU diversity; US legal market ~USD 29.7B in 2024. HCPs (1.07M physicians, 4.2M RNs, 314K pharmacists) influence ~70% of patient choices. Retailers/wholesalers target 20–30% margins; international regulated imports grew ~8% in 2024 (~USD 12B).
| Segment | Size/2024 | Key needs | Drivers |
|---|---|---|---|
| Medical | 38.3B by 2028 | Safety, docs, subscriptions | Clinical data, delivery |
| Recreational | 29.7B US | Flavor, formats, premium | Brand, promotions |
| HCPs | ~5.6M clinicians | Evidence, quality | Guidelines, liability |
| Retail/Intl | 20–30% margins / 12B imports | Supply, compliance | Assortment, contracts |
Cost Structure
Cultivation & processing
Energy, nutrients, labor and facility overhead drive Aurora’s cultivation COGS; Canadian LPs in 2024 reported average cultivation costs near CAD 0.70–1.00 per gram, with energy often 25–40% of that spend. Post-harvest handling, extraction and packaging add materially to per-unit cost. Yield and efficiency programs (automation, LED retrofit) routinely cut spend 10–30%. Scale reduces unit economics as fixed overhead spreads across higher volumes.
Quality & compliance
Testing, audits, and certifications demand continuous investment—industry compliance spending rose with the global regulatory technology and compliance market estimated at 74.1 billion USD in 2024, driving recurring lab and audit fees. Documentation and regulatory filing costs accrue per product lifecycle, while recall preparedness and insurance reserve typically represent 1–3% of revenue for risk-prone sectors. Continuous training programs sustain standards and reduce noncompliance incident rates.
Sales & marketing
Sales & marketing costs center on trade spend—industry trade promotion averages 17% of gross sales (NielsenIQ 2022)—funding merchandising and retailer education programs; digital content and CRM leverage global martech capacity (≈$121B market in 2023) for targeted campaigns; market research and promotions inform pricing and SKUs; events and retailer support budgets cover field teams, POS and joint promotions.
R&D and IP
R&D and IP costs cover breeding, formulation, and clinical studies: preclinical breeding/formulation ~0.5–2M; clinical development ~1–5M (Phase I), 7–20M (Phase II), 20–100M (Phase III) in 2024. Equipment, labs, pilot runs demand 1–10M capex plus 0.5–2M annual ops. Patents/trademarks ~100–500k lifecycle; data management/analytics ~200k–1M/year.
- Breeding/formulation: 0.5–2M
- Clinical trials: 1–100M by phase
- Equipment/labs: 1–10M capex
- IP: 100–500k lifecycle
- Data/analytics: 200k–1M/year
Logistics & distribution
- 3PL market >1T USD (2024)
- Inventory carry 20–30% of value
- Shrink ~1–2%
- Cold-chain premium on storage/transport
- Forecasting/visibility lowers safety stock & freight/duty waste
Curb costs: COGS CAD 0.7–1/g, energy 25–40%
Cultivation COGS ~CAD 0.70–1.00/g with energy 25–40% of spend; yield/automation cut costs 10–30%. Compliance/tech market ~74.1B USD (2024) raising lab/audit fees; recall/insurance ~1–3% revenue. Trade promotion ~17% of gross sales; 3PL market >1T USD (2024) with inventory carry 20–30% value.
| Cost category | Key metric | 2024 benchmark |
|---|---|---|
| Cultivation | COGS per g; energy% | CAD 0.70–1.00; energy 25–40% |
| Compliance | Market size | 74.1B USD |
| Sales & Marketing | Trade promo | 17% sales |
| Logistics | 3PL market; inventory carry | >1T USD; 20–30% |
Revenue Streams
Medical product sales
Medical product sales combine direct-to-patient and pharmacy-dispensed channels (roughly 25/75 split), with higher-margin GMP offerings typically delivering 30–40% gross margins and steady demand; subscription/refill models can lift predictable revenue ~25% and drive ~60% refill retention, while insurance coverage has been shown to increase uptake by up to 35% in comparable product categories in 2024.
Adult-use product sales
Adult-use product sales are primarily wholesale to provincial boards and independent retailers across a broad SKU set, with volume-driven tactics and regular promotional cycles to clear inventory. Active mix management—shifting emphasis to higher-margin SKUs and formats—lifts overall margins. Seasonal demand drops are offset by limited-edition releases that create short-term spikes in sell-through and reorder activity.
International exports
Shipments to regulated overseas markets target higher-margin channels and support Aurora’s international footprint. Long-term supply contracts stabilize volumes and reduce quarter-to-quarter variability. Compliant, GMP-grade product commands premium pricing versus commodity domestic rates. Currency movements matter: 2024 USD/CAD averaged about 1.34, affecting realized CAD revenue from USD sales.
White-label & B2B
White-label and B2B manufacturing lets Aurora leverage excess production capacity to serve a global legal cannabis market valued at about USD 26.9 billion in 2024, converting fixed costs into immediate revenue while bulk oil and distillate sales monetize extraction yields and inventory throughput. Contract terms (typical 12–36 month supply agreements industry-wide) smooth utilization and reduce cyclical downtime, while co-development fees for bespoke formulations provide incremental margin upside and client lock-in.
- Capacity leverage: converts fixed costs to revenue
- Bulk oil/distillate: monetizes extraction output
- Contracts: stabilize utilization, often 12–36 months
- Co-development fees: add high-margin upside
IP & licensing
Aurora monetizes IP and formulations through genetic and formulation licensing to partners, capturing royalties—commonly 2–8% in biotech deals (2024 industry surveys)—for asset-light recurring income; research collaborations deliver upfront and milestone payments, with individual milestones ranging from low‑millions to >$100M in large deals (2024 deal data), while brand licensing expands market reach and revenue diversification.
- royalties: 2–8% (2024)
- milestones: $1M–>$100M per deal (2024)
- asset-light recurring income
- brand licensing = distribution leverage
Med/retail 25/75 - GMP 30-40%, subs ~25%
Medical vs retail mix ~25/75; GMP product margins 30–40% and subscription refills drive ~25% predictable revenue with ~60% retention. International/GMP exports command premiums; 2024 USD/CAD ~1.34 impacts CAD reporting. White‑label/B2B uses excess capacity, supporting global market ~USD 26.9B (2024); royalties 2–8% and milestones $1M–>$100M add asset‑light income.
| Metric | Value (2024) |
|---|---|
| Med/retail split | 25/75 |
| GMP gross margin | 30–40% |
| Subscription lift | ~25% |
| Refill retention | ~60% |
| USD/CAD avg | 1.34 |
| Global market | USD 26.9B |
| Royalties | 2–8% |
| Milestones | $1M–>$100M+ |